Cyclerion Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cyclerion Therapeutics has been growing earnings at an average annual rate of 33.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 14.1% per year.
Key information
33.6%
Earnings growth rate
42.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -14.1% |
| Return on equity | -111.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Cyclerion stock tanks 32% on workforce reduction, clinical development refocus
Oct 06We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate
Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate
Mar 03Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
Oct 26Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021
Jun 21Cyclerion climbs on a series of insider purchases
Jun 08Cyclerion updates on clinical trial progress at webinar
Apr 28Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?
Mar 09What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?
Jan 28
Cyclerion Therapeutics +10.5% after prelim reports
Jan 13Cyclerion Therapeutics announces promotions
Dec 21Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?
Dec 20Cyclerion Therapeutics reports Q3 results
Nov 05Revenue & Expenses BreakdownBeta
How Cyclerion Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -13 | 8 | 0 |
| 30 Sep 23 | 1 | -41 | 11 | 0 |
| 30 Jun 23 | 1 | -29 | 14 | 0 |
| 31 Mar 23 | 1 | -38 | 14 | 0 |
| 31 Dec 22 | 0 | -18 | 13 | 0 |
| 30 Sep 22 | 1 | -25 | 14 | 0 |
| 30 Jun 22 | 2 | -48 | 16 | 0 |
| 31 Mar 22 | 5 | -51 | 19 | 0 |
| 31 Dec 21 | 4 | -52 | 21 | 0 |
| 30 Sep 21 | 4 | -60 | 23 | 0 |
| 30 Jun 21 | 4 | -68 | 27 | 0 |
| 31 Mar 21 | 1 | -71 | 27 | 0 |
| 31 Dec 20 | 2 | -78 | 29 | 0 |
| 30 Sep 20 | 4 | -85 | 32 | 0 |
| 30 Jun 20 | 5 | -93 | 28 | 0 |
| 31 Mar 20 | 6 | -106 | 34 | 0 |
| 31 Dec 19 | 5 | -123 | 34 | 0 |
| 30 Sep 19 | 3 | -128 | 32 | 0 |
| 30 Jun 19 | 2 | -130 | 36 | 0 |
| 31 Mar 19 | 0 | -127 | 31 | -22 |
| 31 Dec 18 | 0 | -115 | 28 | 0 |
| 30 Sep 18 | 0 | -112 | 22 | 24 |
| 30 Jun 18 | 0 | -108 | 19 | 45 |
| 31 Mar 18 | 0 | -99 | 15 | 84 |
| 31 Dec 17 | 0 | -94 | 15 | 79 |
Quality Earnings: CYCN is currently unprofitable.
Growing Profit Margin: CYCN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYCN is unprofitable, but has reduced losses over the past 5 years at a rate of 33.6% per year.
Accelerating Growth: Unable to compare CYCN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYCN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CYCN has a negative Return on Equity (-111.56%), as it is currently unprofitable.